Comprehensive NGS Panel for Pancreatic Adenocarcinoma
For patients with locally advanced or metastatic pancreatic adenocarcinoma who are candidates for anticancer therapy, perform molecular testing that includes actionable somatic mutations: fusions (ALK, NRG1, NTRK, ROS1), mutations (BRAF, BRCA1/2, HER2, KRAS G12C, PALB2), and mismatch repair (MMR) deficiency/microsatellite instability-high (MSI-H) status. 1
Testing Strategy
The NCCN guidelines 1 provide the most direct framework for NGS panel selection in pancreatic cancer:
Core Actionable Targets to Include:
- DNA damage response genes: BRCA1, BRCA2, PALB2, ATM (critical for PARP inhibitor eligibility)
- Targetable driver mutations: KRAS G12C, BRAF, HER2
- Fusion genes: ALK, NTRK, NRG1, ROS1
- MMR deficiency/MSI-H status (for pembrolizumab eligibility, though <1% of cases) 2
Practical Implementation Considerations:
Two-Stage Algorithm Approach: Recent evidence 3 demonstrates that a stratified two-stage approach may be equally effective and more cost-efficient than upfront comprehensive testing:
- Stage 1: Immunohistochemistry for MMR deficiency + targeted 33-gene panel covering common drivers and DNA damage response genes
- Stage 2: Comprehensive testing only if KRAS wild-type, MMR deficiency detected, or molecular tumor board recommendation
This stratified approach identified actionable alterations in 26.6% of cases without missing clinically relevant targets compared to upfront comprehensive panels 3.
Sample Adequacy from EUS-FNB:
EUS-guided fine-needle biopsy provides adequate tissue for NGS in 89.9% of pancreatic malignancies 4. Key technical requirements:
- Minimum tumor cellularity: 20%
- Minimum tumor area: ≥10 mm²
- Success rate improves to 92% specifically in pancreatic ductal adenocarcinoma 4
Critical pitfall: Strict pre-analysis screening criteria may reduce adequacy rates (79.7% vs 98.4% without screening) 4, so avoid overly restrictive sample selection.
Expected Mutation Frequencies:
In pancreatic ductal adenocarcinoma, NGS panels detect:
- KRAS mutations: 87.4% (predominantly codon 12) 4
- TP53: 62.6% 4
- CDKN2A: 20.6% 4
- SMAD4: 19.4% 4
- Actionable mutations: 14.5% of cases 4
Germline Testing:
Separate germline testing is recommended for all patients with confirmed pancreatic cancer, particularly those with family history, young age, or Ashkenazi Jewish ancestry 1. The germline panel should include: BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, PMS2, CDKN2A, TP53, and STK11 1. Germline pathogenic variants are found in approximately 9.9% of patients with suspected hereditary predisposition 5, with ATM and BRCA2 being most frequent.
Clinical Impact and Timing
Major implementation gap: While actionable alterations are detected in 8.8% of patients, only 3.5% ultimately receive genotype-matched therapy 6. This attrition is primarily due to regulatory and companion diagnostic constraints rather than clinical deterioration.
Timing recommendation: Order NGS testing early in the disease course. The median interval from diagnosis to CGP in real-world practice is 259 days 6—this delay significantly limits therapeutic opportunities. Testing should occur at diagnosis of advanced disease, not after multiple lines of therapy.
Therapeutic Implications:
Patients receiving targeted therapy based on molecular profiling demonstrate superior progression-free survival and overall survival compared to those without matched treatment 3. Specific actionable findings include:
- BRCA1/2 or PALB2 mutations: PARP inhibitor eligibility
- MSI-H/dMMR: Pembrolizumab (FDA-approved across tumor types) 2
- KRAS G12C: Emerging targeted therapies
- NTRK fusions: TRK inhibitors
Do not wait for tumor mutation burden results to guide immunotherapy decisions—data remain insufficient for pancreatic cancer, and clear definitions/assay standardization are lacking 2.